Cancer and itch

Seminars in Cutaneous Medicine and Surgery

Volumn 30, Issue 2, 2011, Pages 107-112

  Chiang, Herbert C ^a   Huang, Victor ^a   Cornelius, Lynn A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; BEXAROTENE; BUTORPHANOL; CAPSAICIN; CORTICOSTEROID; DIPHENHYDRAMINE; DOXEPIN; EMOLLIENT AGENT; GABAPENTIN; HYDROXYZINE; LACTATE DEHYDROGENASE; MIRTAZAPINE; NALOXONE; NALTREXONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PREGABALIN; PSORALEN; SERTRALINE; THALIDOMIDE;

BASAL CELL CARCINOMA; BIOPSY; BLOOD CELL COUNT; BLOOD DYSCRASIA; CANCER INVASION; CANCER RISK; CHOLESTASIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLOTHING; COMPUTER ASSISTED TOMOGRAPHY; COOLING; CORTICOSTEROID THERAPY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE RELEASE; DERMATITIS HERPETIFORMIS; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; EOSINOPHILIA; EOSINOPHILIC DERMATOSIS; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY TUMOR; LACTATE DEHYDROGENASE BLOOD LEVEL; LARYNX TUMOR; LEUKOCYTE DIFFERENTIAL COUNT; LIVER FUNCTION TEST; LUNG TUMOR; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MANTLE CELL LYMPHOMA; MEDICAL HISTORY; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; NOCICEPTION; NONHODGKIN LYMPHOMA; NONHUMAN; PAPULE; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PHOTOTHERAPY; PHYSICAL EXAMINATION; RASH; REVIEW; SEZARY SYNDROME; SKIN CANCER; SKIN CARE; SKIN NODULE; SKIN PRURITUS; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR; TOPICAL TREATMENT; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UREMIA; URETER OBSTRUCTION;

ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTIPRURITICS; ANTIPSYCHOTIC AGENTS; HUMANS; NEOPLASMS; PRURITUS;

EID: 79960416737     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.1016/j.sder.2011.05.003     Document Type: Review

References (52)

1. Yosipovitch G. Chronic pruritus: A paraneoplastic sign. Dermatol Ther 2010, 23:590-596.
2. Elmer K.B., George R.M. Cutaneous T-cell lymphoma presenting as benign dermatoses. Am Fam Physician 1999, 59:2809-2813.
3. Hon K.L., Lam M.C., Leung T.F., et al. A malignant itch. J Natl Med Assoc 2006, 98:1992-1994.
4. Zylicz Z., Krajnik M. Pruritus in the course of malignancy. Pruritus 2010, 191-194. Springer, London. L. Misery, S. Stander (Eds.).
5. Polat M., Oztas P., Ilhan M.N., et al. Generalized pruritus: A prospective study concerning etiology. Am J Clin Dermatol 2008, 9:39-44.
6. Zirwas M.J., Seraly M.P. Pruritus of unknown origin: A retrospective study. J Am Acad Dermatol 2001, 45:892-896.
7. Dawn A.G., Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006, 54:527-531.
8. Cormia F.E. Pruritus, an uncommon but important symptom of systemic carcinoma. Arch Dermatol 1965, 92:36-39.
9. Byrd J.A., Scherschun L., Chaffins M.L., et al. Eosinophilic dermatosis of myeloproliferative disease: Characterization of a unique eruption in patients with hematologic disorders. Arch Dermatol 2001, 137:1378-1380.
10. Weed R.I. Exaggerated delayed hypersensitivity to mosquito bites in chronic lymphocytic leukemia. Blood 1965, 26:257-268.
11. Barzilai A., Shpiro D., Goldberg I., et al. Insect bite-like reaction in patients with hematologic malignant neoplasms. Arch Dermatol 1999, 135:1503-1507.
12. Davis M.D., Perniciaro C., Dahl P.R., et al. Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: A clinical, histopathologic, and immunopathologic study of eight patients. J Am Acad Dermatol 1998, 39:27-35.
13. Askling J., Linet M., Gridley G., et al. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002, 123:1428-1435.
14. Shirani Z., Kucenic M.J., Carroll C.L., et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol 2004, 29:273-276.
15. Rubenstein M., Duvic M. Cutaneous manifestations of Hodgkin's disease. Int J Dermatol 2006, 45:251-256.
16. Gobbi P.G., Attardo-Parrinello G., Lattanzio G., et al. Severe pruritus should be a B-symptom in Hodgkin's disease. Cancer 1983, 51:1934-1936.
17. Demierre M.F., Gan S., Jones J., et al. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006, 107:2504-2511.
18. Meyer N., Paul C., Misery L. Pruritus in cutaneous T-cell lymphomas: Frequent, often severe and difficult to treat. Acta Derm Venereol 2010, 90:12-17.
19. Duval A., Dubertret L. Aprepitant as an antipruritic agent?. N Engl J Med 2009, 361:1415-1416.
20. Gerami P., Rosen S., Kuzel T., et al. Folliculotropic mycosis fungoides: An aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol 2008, 144:738-746.
21. Negin B.P., Riedel E., Oliveria S.A., et al. Symptoms and signs of primary melanoma: Important indicators of Breslow depth. Cancer 2003, 98:344-348.
22. Euvrard S., Kanitakis J., Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003, 348:1681-1691.
23. Jones E.A., Bergasa N.V. Why do cholestatic patients itch?. Gut 1996, 38:644-645.
24. Wang H., Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 2010, 49:1-11.
25. Phan N.Q., Bernhard J.D., Luger T.A., et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: A review. J Am Acad Dermatol 2009, 63:680-688.
26. Lidstone V., Thorns A. Pruritus in cancer patients. Cancer Treat Rev 2001, 27:305-312.
27. Steward W.P., Scarffe J.H., Austin R., et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. Br J Cancer 1989, 59:142-145.
28. Lee S.H., Baig M., Rusciano V., et al. Novel management of pruritus in patients treated with IL-2 for metastatic renal cell carcinoma and malignant melanoma. J Immunother 2010, 33:1010-1013.
29. Sliesoraitis S., Chikhale P.J. Carboplatin hypersensitivity. Int J Gynecol Cancer Off J Int Gynecol Cancer Society 2005, 15:13-18.
30. Bryant R. Use of a protocol to minimize hypersensitivity reactions with asparaginase administration. J Intraven Nurs Off Publ Intravenous Nurses Society 2001, 24:169-173.
31. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014.
32. Lokich J., Anderson N. Paclitaxel hypersensitivity reactions: A role for docetaxel substitution. Ann Oncol 1998, 9:573.
33. Vincenzi B., Tonini G., Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010, 363:397-398.
34. Bolognia J.L., Cooper D.L., Glusac E.J. Toxic erythema of chemotherapy: A useful clinical term. J Am Acad Dermatol 2008, 59:524-529.
35. Patel K.N., Dong X. An itch to be scratched. Neuron 2010, 68:334-339.
36. Papadavid E., Economidou J., Psarra A., et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2003, 148:709-718.
37. Dummer R., Heald P.W., Nestle F.O., et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 1996, 88:1383-1389.
38. Sonkoly E., Muller A., Lauerma A.I., et al. IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117:411-417.
39. Grimstad O., Sawanobori Y., Vestergaard C., et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: A model of atopic dermatitis. Exp Dermatol 2009, 18:35-43.
40. Andrew D., Craig A.D. Spinothalamic lamina I neurons selectively sensitive to histamine: A central neural pathway for itch. Nat Neurosci 2001, 4:72-77.
41. Sun Y.G., Chen Z.F. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007, 448:700-703.
42. Steinhoff M., Neisius U., Ikoma A., et al. Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. J Neurosci 2003, 23:6176-6180.
43. Sun Y.G., Zhao Z.Q., Meng X.L., et al. Cellular basis of itch sensation. Science 2009, 325:1531-1534.
44. Gorge T., Schiller M. Pruritus in cutaneous T-cell Lymphoma. Pruritus 2010, 121-124. Springer, London. L. Misery, S. Stander (Eds.).
45. Gooding S.M., Canter P.H., Coelho H.F., et al. Systematic review of topical capsaicin in the treatment of pruritus. Int J Dermatol 2010, 49:858-865.
46. Ständer S., Böckenholt B., Schürmeyer-Horst F., et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: Results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009, 89:45-51.
47. Demierre M.F., Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 2006, 55:543-544.
48. Davis M.P., Frandsen J.L., Walsh D., et al. Mirtazapine for pruritus. J Pain Symptom Manage 2003, 25:288-291.
49. Daly B.M., Shuster S. Antipruritic action of thalidomide. Acta Derm Venereol 2000, 80:24-25.
50. Gonçalves F. Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease. Am J Hosp Palliat Care 2010, 27:486-487.
51. Bonkowski J., Vermeulen L.C., Kolesar J.M. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes. J Oncol Pharm Pract 2010, 16:223-232.
52. Vincenzi B., Fratto M.E., Santini D., et al. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer 2010, 18:1229-1230.